Follicum has announced that the European Patent Office (EPO) has approved a patent which refers to the company’s novel peptides that are being developed to treat diabetes.
The approval follows the previous provisional approval by the EPO announced on March 20, 2020. The approval provides protection for the company’s peptides and their use to treat diabetes in Europe until 2038.
Similar patents have previously been approved in the United States. In addition, Follicum has a corresponding patent application under review by authorities in China, Japan, India, Canada, South Korea, Singapore, Israel and Australia.
“It is a declaration of strength that the world’s two largest patent offices, USPTO and EPO, have now approved Follicum’s patents in the field of diabetes therapy. This provides stable and robust protection for our product candidates and their use,” says Follicum’s CEO, Jan Alenfall.